Travere Therapeutics, Inc. — News

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations.

businesswire.com - 2026-07-28 16:30:00

NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

prnewswire.com - 2026-07-27 08:50:00

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

globenewswire.com - 2026-07-16 21:43:19

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

globenewswire.com - 2026-07-16 21:43:00

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement s.

businesswire.com - 2026-07-10 17:00:00

HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat

gurufocus.com - 2026-07-08 01:00:00

Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.

seekingalpha.com - 2026-07-03 04:37:04

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO.

businesswire.com - 2026-06-16 16:30:00

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.

businesswire.com - 2026-06-11 17:00:00

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 13:08:31

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Pati.

businesswire.com - 2026-06-04 10:09:00

HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen

gurufocus.com - 2026-06-04 00:00:00

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

seekingalpha.com - 2026-06-02 11:32:14

Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held ​biotech Everest Medicines to develop and ‌commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.

reuters.com - 2026-06-02 08:07:41

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f

gurufocus.com - 2026-06-02 08:00:00

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. “Civorebrutinib represents a strategic and complementary.

businesswire.com - 2026-06-02 07:01:00

Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.

fool.com - 2026-05-28 08:07:09

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan.

businesswire.com - 2026-05-27 16:05:00

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 19:30:45

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s.

businesswire.com - 2026-05-12 17:00:00

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E.

businesswire.com - 2026-05-07 16:30:00

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million. Travere also granted the underwriters of the.

businesswire.com - 2026-05-06 22:28:00

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $60 million aggregate principal amount of Notes, solely to cover over-allotments. As described in more detail below, Trav.

businesswire.com - 2026-05-05 16:01:00

Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.

benzinga.com - 2026-05-05 14:41:08

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 07:21:15

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-04 19:01:13

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.

zacks.com - 2026-05-04 18:10:20

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its first quarter 2026 financial results and provided a corporate update. “This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI's foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and.

businesswire.com - 2026-05-04 16:01:00